Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer

被引：13

作者：

Heigener, David F. ^{[1
,2
,3
]}

Kerr, Keith M. ^{[4
]}

Laing, Gavin M. ^{[4
]}

Mok, Tony S. K. ^{[5
]}

Moiseyenko, Fedor V. ^{[6
,7
]}

Reck, Martin ^{[3
,8
,9
]}

机构：

[1] Helios Klinikum Schleswig, Dept Pulmonol, Schleswig, Germany

[2] Univ Kiel, Kiel, Germany

[3] Airway Res Ctr North German Ctr Lung Res DZL, Grosshansdorf, Germany

[4] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[5] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[6] Inst Oncol NN Petrov St Petersburg, Pesochny, Russia

[7] St Petersburg City Canc Ctr, St Petersburg, Russia

[8] LungenClin Grosshansdorf, Grosshansdorf, Germany

[9] Univ Lubeck, Lubeck, Germany

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 16期

关键词：

PLATINUM-BASED CHEMOTHERAPY; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; EGFR MUTATIONS; INTERNATIONAL ASSOCIATION; PHASE-III; AFATINIB; MULTICENTER; CRIZOTINIB; GEFITINIB;

D O I：

10.1158/1078-0432.CCR-18-1894

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.

引用

页码：4881 / 4887

页数：7

共 50 条

[31] How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
Peters, S.
Reck, M.
Smit, E. F.
Mok, T.
Hellmann, M. D.
ANNALS OF ONCOLOGY, 2019, 30 (06) : 884 - 896
[32] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
Olivier Bylicki
Helene Barazzutti
Nicolas Paleiron
Jacques Margery
Jean-Baptiste Assié
Christos Chouaïd
BioDrugs, 2019, 33 : 159 - 171
[33] Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
Engle, Jeff
Kolesar, Jill
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (22) : 1933 - 1938
[34] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Popat, Sanjay
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
[35] First-line management of advanced non-small-cell lung cancer: can we do better?
Chouaid, Christos
Monnet, Isabelle
Auliac, Jean-Bernard
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1643 - 1648
[36] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
Argiris, A
Mittal, N
LUNG CANCER, 2004, 43 (03) : 317 - 322
[37] Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer A Brazilian Center Experience
Fontes Jardim, Denis Leonardo
Gagliato, Debora de Melo
Ribeiro, Karina Braga
Shimada, Andrea Kazumi
Katz, Artur
DRUGS IN R&D, 2012, 12 (04) : 207 - 216
[38] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Merimsky, O.
Cheng, A. C.
Reck, M.
Au, S. K.
von Pawel, J.
ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
[39] Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer
Decatris, Marios P.
O'Byrne, Kenneth J.
FUTURE ONCOLOGY, 2016, 12 (15) : 1805 - 1822
[40] First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era
Capelletto, Enrica
Novello, Silvia
Scagliotti, Giorgio V.
FUTURE ONCOLOGY, 2014, 10 (06) : 1081 - 1093

← 1 2 3 4 5 →